Latest Articles
Mum’s common female issue turns ‘terminal’ - news.com.au
Mum’s common female issue turns ‘terminal’ news.com.au
Published: July 3, 2024, 7 a.m.
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis - 9News
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis 9News
Published: July 2, 2024, 7 a.m.
Exploring oak processionary caterpillar induced lepidopterism (part 2): ex vivo bio-assays unmask the role of TRPV1.
As human skin comes into contact with the tiny hairs or setae of the oak processionary caterpillar, Thaumetopoea processionea, a silent yet intense chemical confrontation occurs. The result is a …
Published: June 28, 2024, midnight
Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI - Medical Xpress
Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI Medical Xpress
Published: June 26, 2024, 7 a.m.
New insights into molecular mechanisms underlying malignant transformation of endometriosis: BANCR promotes miR-612/CPNE3 pathway activity.
Does LncRNA BANCR promote the malignant transformation of endometriosis by activating the miR-612/CPNE3 pathway?
Published: June 21, 2024, midnight
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International
Published: June 20, 2024, 7 a.m.
FDA approves MSD’s KEYTRUDA for endometrial carcinoma - Pharmaceutical Technology
FDA approves MSD’s KEYTRUDA for endometrial carcinoma Pharmaceutical Technology
Published: June 18, 2024, 7 a.m.
Novel immunotherapy combination approved for endometrial cancer - European Pharmaceutical Review
Novel immunotherapy combination approved for endometrial cancer European Pharmaceutical Review
Published: June 18, 2024, 7 a.m.
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval - FiercePharma
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval FiercePharma
Published: June 18, 2024, 7 a.m.
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? - FiercePharma
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? FiercePharma
Published: June 17, 2024, 7 a.m.
Link copied to clipboard!